CTXR — Citius Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology
$0.59
+$0.02 (+3.65%)
Citius Pharmaceuticals Inc (CTXR) is a biotechnology company listed on NASDAQ. It is led by Leonard L. Mazur, based in 11 Commerce Drive, Cranford, NJ, United States, 07016, with about 23 employees. Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Net income was -$9.2M. CTXR currently screens at market cap $13.4M.
Use this CTXR page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CTXR quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CTXR SEC filings page. Lician reads the product cache first so this HTML stays unique to Citius Pharmaceuticals Inc even when a live quote feed is slow.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Key Statistics
Market Cap
$13.41M
Volume
441,424
Previous Close
$0.60
Day Range
$0.57 – $0.61
EPS
-$5.97
Revenue
$0.00
Net Income
-$39.43M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
23
CTXR Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$39.43M | -$32.54M | -$33.64M | -$23.05M |
| EPS (Diluted) | -$5.97 | -$5.57 | -$0.23 | -$0.23 |
Total Assets
$116.65M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.25M
Operating Cash Flow
-$28.20M
Free Cash Flow
$0.00
Citius Pharmaceuticals Inc Company Information
- Co-Founder, CEO, Chairman & Secretary
- Leonard L. Mazur
- Headquarters
- 11 Commerce Drive, Cranford, NJ, United States, 07016
- Website
- citiuspharma.com
- Phone
- 908 967 6677
- IPO / Founded
- 2017-07-06
- Sector
- Healthcare
- Industry
- Biotechnology